Alnylam Pharmaceuticals is a biopharmaceutical company focused on the development of therapies based on RNA interference (RNAi) technology. Its core products include treatments for genetic diseases and conditions related to liver and cardiovascular health. Major business segments encompass rare diseases and cardiovascular diseases, with primary revenue sources stemming from product sales and collaborations with other pharmaceutical companies.
The investment profile of Alnylam Pharmaceuticals is more aligned with growth investors, given its focus on innovative therapies and potential market expansion. However, the high risk associated with its volatility and market performance may deter conservative investors. The stock may appeal to those with a longer investment horizon who are willing to accept higher risk for potential future gains.
| Datum | Vorher | Nachher | Grund |
|---|---|---|---|
| 2026-06-03 02:58 | Halten | Verkaufen | Weak momentum and high risk overshadow potential growth. |
| 2026-05-24 02:31 | Verkaufen | Halten | Strong EPS surprise, but negative momentum raises concerns. |
| 2026-05-16 02:47 | Halten | Verkaufen | Weak momentum and high risk overshadow positive fundamentals. |
| Datum | Analyst | Action | Ziel | Preis damals |
|---|---|---|---|---|
| 2026-05-01 15:46 | Morgan Stanley | Ziel erhöht | 360 → 370 | 301.4499 |
| 2026-05-01 13:04 | Bernstein | Ziel gesenkt | 448 → 447 | 302.85001 |
| 2026-02-17 12:18 | Canaccord Genuity | Ziel erhöht | 415 → 429 | 314.4 |
